
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous ...
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more …